The meningococcus tamed?
Serogroup B Neisseria meningitidis is a frequent cause of invasive meningococcal disease, yet there are no effective vaccines suitable for routine immunisation. Limited efficacy has been shown with meningococcal outer membrane vacccines in children 4 years and older. Here we review the status of current research and consider new approaches to development of meningococcal serogroup B vaccines.
Pollard
A J
AJ
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK. andrew.pollard@paediatrics.ox.ac.uk
Moxon
E R
ER
D001425:Bacterial Outer Membrane Proteins / Q000276:immunology; D002648:Child; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D005098:Exotoxins / Q000276:immunology; D006801:Humans; D008070:Lipopolysaccharides / Q000276:immunology; D008585:Meningitis, Meningococcal / Q000517:prevention & control*; D022401:Meningococcal Vaccines; D009345:Neisseria meningitidis / Q000145:classification
D001425:Bacterial Outer Membrane Proteins; D005098:Exotoxins; D008070:Lipopolysaccharides; D022401:Meningococcal Vaccines